SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay
Open accessPublished version of a preprint
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Antibody detection of prior SARS-CoV-2 infection depends on severity, assay, and timing with implications for serosurveillance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)
Herdman, M., Gudex, C., Lloyd, A., Janssen, M., Kind, P., Parkin, D., Bonsel, G., & Badia, X. (2011) · Quality of Life Research · doi:10.1007/s11136-011-9903-x · Cited by 9,795 · cited 1×
“Participants were questioned regarding the presence, duration (in days), and current status of a list of COVID-19 symptoms and additional somatic symptoms derived from the Patient Health Questionnaire (21), as well as measures of quality of life derived from the EQ-5D-5L Instrument (22).”
Richardson, S., Hirsch, J. S., Narasimhan, M., Crawford, J. M., McGinn, T., Davidson, K. W., and the Northwell COVID-19 Research Consortium, Barnaby, D. P., Becker, L. B., Chelico, J. D., et al. (2020) · JAMA · doi:10.1001/jama.2020.6775 · Cited by 9,254
The PHQ-15: Validity of a New Measure for Evaluating the Severity of Somatic Symptoms
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2002) · Psychosomatic Medicine · doi:10.1097/00006842-200203000-00008 · Cited by 3,298
Antibody responses to SARS-CoV-2 in patients with COVID-19
Long, Q.-X., Liu, B.-Z., Deng, H.-J., Wu, G.-C., Deng, K., Chen, Y.-K., Liao, P., Qiu, J.-F., Lin, Y., Cai, X.-F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0897-1 · Cited by 2,876
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections
Long, Q.-X., Tang, X.-J., Shi, Q.-L., Li, Q., Deng, H.-J., Yuan, J., Hu, J.-L., Xu, W., Zhang, Y., Lv, F.-J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0965-6 · Cited by 2,686
Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019
Zhao, J., Yuan, Q., Wang, H., Liu, W., Liao, X., Su, Y., Wang, X., Yuan, J., Li, T., Li, J., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa344 · Cited by 2,607
A serological assay to detect SARS-CoV-2 seroconversion in humans
Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T. H. O., Chromikova, V., McMahon, M., Jiang, K., Arunkumar, G. A., Jurczyszak, D., Polanco, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0913-5 · Cited by 1,769
Evolution of antibody immunity to SARS-CoV-2
Gaebler, C., Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Tokuyama, M., Cho, A., Jankovic, M., Schaefer-Babajew, D., Oliveira, T. Y., et al. (2021) · Nature · doi:10.1038/s41586-021-03207-w · Cited by 1,674 · cited 1×
“These two assays, along with a research-use assay using direct detection (RBD-LIPS), were the only ones to demonstrate increasing rather than decreasing antibody signal over time, possibly due to continued affinity maturation of the antibody response (18) playing a larger role in detection with this format.”
MethodSeow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K. J. A., Hemmings, O., O’Byrne, A., Kouphou, N., Galao, R. P., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00813-8 · Cited by 1,419
Cited by
Miller, J. M., Binnicker, M. J., Campbell, S., Carroll, K. C., Chapin, K. C., Gonzalez, M. D., Harrington, A., Jerris, R. C., Kehl, S. C., Leal, S. M., et al. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae104 · Cited by 376
Ely, E. W., Brown, L. M., & Fineberg, H. V. (2024) · New England Journal of Medicine · doi:10.1056/nejmsb2408466 · Cited by 340
Peluso, M. J., Lu, S., Tang, A. F., Durstenfeld, M. S., Ho, H.-E., Goldberg, S. A., Forman, C. A., Munter, S. E., Hoh, R., Tai, V., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab490 · Cited by 320
Self-citationBarber, R. M., Sorensen, R. J. D., Pigott, D. M., Bisignano, C., Carter, A., Amlag, J. O., Collins, J. K., Abbafati, C., Adolph, C., Allorant, A., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00484-6 · Cited by 298
Jones, J. M., Stone, M., Sulaeman, H., Fink, R. V., Dave, H., Levy, M. E., Di Germanio, C., Green, V., Notari, E., Saa, P., et al. (2021) · JAMA · doi:10.1001/jama.2021.15161 · Cited by 201
Self-citation
Metadata
- Authors
- Peluso, M. J., Takahashi, S., Hakim, J., Kelly, J. D., Torres, L., Iyer, N. S., Turcios, K., Janson, O., Munter, S. E., Thanh, C., Donatelli, J., Nixon, C. C., Hoh, R., Tai, V., Fehrman, E. A., Hernandez, Y., Spinelli, M. A., Gandhi, M., Palafox, M.-A., Vallari, A., Rodgers, M. A., Prostko, J., Hackett, J., Trinh, L., Wrin, T., Petropoulos, C. J., Chiu, C. Y., Norris, P. J., DiGermanio, C., Stone, M., Busch, M. P., Elledge, S. K., Zhou, X. X., Wells, J. A., Shu, A., Kurtz, T. W., Pak, J. E., Wu, W., Burbelo, P. D., Cohen, J. I., Rutishauser, R. L., Martin, J. N., Deeks, S. G., Henrich, T. J., Rodriguez-Barraquer, I., & Greenhouse, B.
- Affiliations
- University of California, San Francisco (US)
- Abbott (United States) (US)
- Monogram Biosciences Inc., South San Francisco, CA, USA.
- Vitalant Research Institute (US)
- Vitalant Research Institute, San Francisco, CA, USA.
- Chan Zuckerberg Biohub San Francisco (US)
- National Institutes of Health (US)
- Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA.
- Corresponding author
- Peluso, Michael J.
- Takahashi, Saki
- Hakim, Jill
- Henrich, Timothy J.
- Greenhouse, Bryan
- ORCID
- Peluso, Michael J.
- Takahashi, Saki
- Hakim, Jill
- Kelly, J. Daniel
- Torres, Leonel
- Iyer, Nikita S.
- Thanh, Cassandra
- Hoh, Rebecca
- Tai, Viva
- Hernandez, Yanel
- Spinelli, Matthew A.
- Gandhi, Monica
- Palafox, Mary-Ann
- Vallari, Ana
- Rodgers, Mary A.
- Petropoulos, Christos J.
- Chiu, Charles Y.
- Norris, Philip J.
- DiGermanio, Clara
- Stone, Mars
- Busch, Michael P.
- Elledge, Susanna K.
- Zhou, Xin X.
- Wells, James A.
- Shu, Albert
- Kurtz, Theodore W.
- Pak, John E.
- Wu, Wesley
- Burbelo, Peter D.
- Cohen, Jeffrey I.
- Rutishauser, Rachel L.
- Martin, Jeffrey N.
- Deeks, Steven G.
- Henrich, Timothy J.
- Rodriguez-Barraquer, Isabel
- Greenhouse, Bryan
- Venue
- Science Advances
- Published
- 2021-07-30
- Volume
- 7
- Issue
- 31
- ISSN
- 2375-2548 (ISSN-L)
- PMC
- PMC8324059
- OpenAlex
- W3192055536
- Cited by
- 130
- References
- 29
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 18 · 2023: 23 · 2022: 52 · 2021: 26
- FWCI
- 9.41
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Science Advances (publishedVersion, cc-by)
- medRxiv (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- PubMed Central (submittedVersion, cc-by)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (T32 AI60530-12)
- National Heart, Lung, and Blood Institute (R01 HL105704, R33- 29077)
- National Institute of Allergy and Infectious Diseases (3R01AI141003-03S1, R01AI158013)
- National Institute of Dental and Craniofacial Research
- Chan Zuckerberg Biohub Investigator Fund
- MIDAS Coordination Center (MIDASNI2020)
- Instituto Nacional de Ciência e Tecnologia Midas (MIDASNI2020)
- Damon-Runyon Cancer Research Fellowship
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 detection and testing
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- SARS-CoV-2, COVID-19 pandemic, antibody response, serological surveillance, disease severity, seroreversion, neutralizing antibodies, spike protein antibodies, nucleocapsid antibodies, mild infection, assay variability
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay. https://app.cochat.ai/papers/10.1126/sciadv.abh3409
- The paper
- Peluso, M. J., Takahashi, S., Hakim, J., Kelly, J. D., Torres, L., Iyer, N. S., Turcios, K., Janson, O., Munter, S. E., Thanh, C., Donatelli, J., Nixon, C. C., Hoh, R., Tai, V., Fehrman, E. A., Hernandez, Y., Spinelli, M. A., Gandhi, M., Palafox, M.-A., . . . Greenhouse, B. (2021). SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay. Science Advances. https://doi.org/10.1126/sciadv.abh3409
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.